This company listing is no longer active
LCIN.Q Stock Overview
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Lannett Company, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$3.72 |
| 52 Week Low | US$0.01 |
| Beta | 0.94 |
| 1 Month Change | 48.25% |
| 3 Month Change | -98.21% |
| 1 Year Change | -98.68% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.41% |
Recent News & Updates
Recent updates
Lannett announces 1-for-4 reverse stock split
Jan 25Lannett gains on patent deal for biosimilar insulin device
Nov 07Lannett gets FDA approval to manufacture Numbrino® at Seymour plant
Oct 21Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's Estimates
Sep 01
Lannett GAAP EPS of -$2.30, revenue of $74.19M
Aug 24Lannett: A Self-Inflicted Crisis
Feb 22Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts
Feb 05A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)
Nov 05Is Lannett Company (NYSE:LCI) A Risky Investment?
Jun 20Is Lannett Company (NYSE:LCI) A Risky Investment?
Mar 18Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)
Feb 11
What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 15Is Lannett Company (NYSE:LCI) Using Too Much Debt?
Dec 11Shareholder Returns
| LCIN.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 12.7% | 3.2% | -1.1% |
| 1Y | -98.7% | -12.4% | 9.1% |
Return vs Industry: LCIN.Q underperformed the US Pharmaceuticals industry which returned 4% over the past year.
Return vs Market: LCIN.Q underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| LCIN.Q volatility | |
|---|---|
| LCIN.Q Average Weekly Movement | 50.7% |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: LCIN.Q's share price has been volatile over the past 3 months.
Volatility Over Time: LCIN.Q's weekly volatility has increased from 28% to 51% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1942 | 564 | Tim Crew | www.lannett.com |
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications.
Lannett Company, Inc. Fundamentals Summary
| LCIN.Q fundamental statistics | |
|---|---|
| Market cap | US$319.24k |
| Earnings (TTM) | -US$259.09m |
| Revenue (TTM) | US$310.67m |
Is LCIN.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LCIN.Q income statement (TTM) | |
|---|---|
| Revenue | US$310.67m |
| Cost of Revenue | US$254.66m |
| Gross Profit | US$56.01m |
| Other Expenses | US$315.10m |
| Earnings | -US$259.09m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.06 |
| Gross Margin | 18.03% |
| Net Profit Margin | -83.40% |
| Debt/Equity Ratio | -152.4% |
How did LCIN.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/21 15:14 |
| End of Day Share Price | 2023/06/16 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lannett Company, Inc. is covered by 12 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| Sumant Satchidanand Kulkarni | BofA Global Research |
| John Newman | Canaccord Genuity |